Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N C P Cross

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Leukemia|October 26, 2002
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyA Hochhaus, S Kreil, A S Corbin, et al.
British Journal of Cancer|October 12, 2004
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplificationD J Bunyan, D M Eccles, J Sillibourne, et al.
Leukemia|January 12, 2007
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cellsB Crescenzi, A Chase, R La Starza, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Leukemia|July 2, 2005
Age has a profound effect on the incidence and significance of chromosome abnormalities in myelomaF M Ross, A H Ibrahim, A Vilain-Holmes, et al.
Leukemia|January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|August 13, 2010
Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formationJ Score, M J Calasanz, O Ottman, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|November 7, 2008
The molecular anatomy of the FIP1L1-PDGFRA fusion geneC Walz, J Score, J Mix, et al.
Leukemia|July 11, 2006
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myelomaL Chiecchio, R K M Protheroe, A H Ibrahim, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Leukemia|October 26, 2002
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyA Hochhaus, S Kreil, A S Corbin, et al.
British Journal of Cancer|October 12, 2004
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplificationD J Bunyan, D M Eccles, J Sillibourne, et al.
Leukemia|January 12, 2007
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cellsB Crescenzi, A Chase, R La Starza, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Leukemia|July 2, 2005
Age has a profound effect on the incidence and significance of chromosome abnormalities in myelomaF M Ross, A H Ibrahim, A Vilain-Holmes, et al.
Leukemia|January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|August 13, 2010
Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formationJ Score, M J Calasanz, O Ottman, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|November 7, 2008
The molecular anatomy of the FIP1L1-PDGFRA fusion geneC Walz, J Score, J Mix, et al.
Leukemia|July 11, 2006
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myelomaL Chiecchio, R K M Protheroe, A H Ibrahim, et al.
Pageof 5